Other content tagged: Respiratory Syncytial Virus

Platinum Partner AstraZeneca produced and funded “Sounds of RSV” to support awareness of symptoms

  Our partnership with AstraZeneca is part of the EFCNI’s ongoing dedication to raising awareness amongst parents and healthcare professionals about the symptoms of RSV infection and how it can be prevented. With around 33 million acute lower respiratory infections caused each year, RSV infection is one of the most common causes of early life wheezing illness.[1,2] Babies who are born prematurely or who have underlying health issues such as heart or…
Read more


In 2021, the season of respiratory syncytial virus (RSV) infections was exceptional in terms of the very early onset and the enormously high numbers of hospitalised children. Thus, the last season showed very clearly: RSV is a major health threat to children under two years of age. In most cases of RSV, children develop only mild, cold-like symptoms. However, a number of children suffer from a severe course of the infection with severe respiratory distress and accompanying symptoms that need…
Read more

EFCNI Welcomes Platinum Partner AstraZeneca to Raise Awareness of RSV

    With EFCNI’s long standing leadership in preterm infants’ health and well-being, and AstraZeneca’s heritage in the RSV space, this partnership aims to increase awareness and educate parents and healthcare providers about the signs and symptoms of this challenging condition and available preventative options. In celebration of EFCNI’s platinum partnership with AstraZeneca, we had the opportunity to sit down with three leaders from AstraZeneca’s RSV team to ask about their work within the disease area. RSV is a very common,…
Read more